Novel Crystalline Forms of Entacapone and Production Thereof

Information

  • Patent Application
  • 20080076825
  • Publication Number
    20080076825
  • Date Filed
    December 27, 2004
    19 years ago
  • Date Published
    March 27, 2008
    16 years ago
Abstract
The invention relates to three novel forms of entacapone. These are peripheral and selective COMT inhibitors which in combination with levodopa and decarboxylase inhibitors can be used to treating Parkinson's syndrome. Said novel forms arise by crystallization of entacapone in respectively determined conditions. In certain cases, entacapone can be used as a raw product, in a special case it can be used in situ as the product of Knoevenagel condensation of 3,4-dihydroxy-5-nitro-benzaldehyde and N,N-diethyl-2-cyanoacetamide. Also disclosed are improvements of said condensation in relation to the catalyst and the production of the two components thereof.
Description
EXAMPLE 1
Preparation of 3,4-dihydroxy-5-nitrobenzaldehyde

175.0 g of 5-nitrovanillin and 135.1 g of aluminum chloride were suspended in 774.2 g of chlorobenzene to form an orange-red suspension. 319.9 g of pyridine were then added dropwise in such a way that the internal temperature did not exceed 25° C. The deep red suspension obtained after the addition was heated to an internal temperature of 70-80° C. When the reaction was complete, a solution of 525 g of water and 603.75 g of 32% hydrochloric acid (semiconcentrated hydrochloric acid) was added slowly to the reaction mixture. The hydrolysis initially produced a deep red two-phase mixture, from which a yellow solid precipitated out towards the end. When the addition of the semi-concentrated hydrochloric acid had ended, the suspension was concentrated to half the volume under vacuum. 475 g of water were then added to the suspension and the mixture was heated to the boil, during which the solid dissolved. After 5-10 min under reflux, the solution was left to cool slowly and a solid then precipitated out. The suspension was cooled to 20-25° C., stirred at this temperature and then filtered with suction. The solid was washed with 1000 g of water and dried at 60° C. under vacuum (yield: 152.47 g).


EXAMPLE 2
Preparation of N,N-diethyl-2-cyanoacetamide

25.0 g of cyanoacetic acid were dissolved in 163.08 g of ethyl acetate. 21.70 g of diethylamine were added slowly to the resulting colorless solution in such a way that the internal temperature did not exceed 25° C. A solution of 61.10 g of dicyclohexylcarbodiimide in 54.06 g of ethyl acetate was then added dropwise and a solid precipitated out slowly. After the addition the suspension was stirred overnight at 35-40° C. When the reaction had ended, the suspension was cooled to 20-25° C. and filtered with suction. The solid was rinsed with 64.87 g of ethyl acetate. The combined filtrates were concentrated under vacuum and a solid precipitated out. The suspension was taken up in 45.05 g of ethyl acetate, the mixture was stirred at 20-25° C. and the solid was filtered off and rinsed with 45.05 g of ethyl acetate. The combined filtrates were concentrated under vacuum again. The residue was taken up in 18.02 g of ethyl acetate, the mixture was filtered, the material on the filter was rinsed with 13.52 g of ethyl acetate and the filtrate was concentrated under vacuum. The crude product obtained was then distilled under vacuum (vapor temperature: 107-110° C., pressure: 4×10−1-2×10−2 Torr) to give 39.25 g (89%) of 2-cyanoacetic acid diethylamide in the main fraction.


EXAMPLE 3
Preparation of Entacapone in the Polymorphous Form D
3.1. Knoevenagel Condensation and Subsequent Isomerization

A mixture of 120 g of 3,4-dihydroxy-5-nitrobenzaldehyde, 94.56 g of N,N-diethyl-2-cyanoacetamide, 3.76 g of acetic acid and 4.58 g of diethylamine in 432 g of toluene was heated in a water separator. When the reaction was almost complete (E/Z isomer ratio=70/30), 109 g of acetonitrile and 38.4 g of active charcoal were added and the mixture was refluxed for 0.5-4 h. While still hot, the suspension was filtered on 14.0 g of Célite and the solid was then rinsed with 66.1 g of acetonitrile. The solution was placed in a receiver with 432 g of toluene. The temperature was not supposed to exceed 20° C. When the addition was complete, 43.2 g of a 33% solution of HBr in acetic acid were added and the mixture was stirred overnight at room temperature. The suspension was then cooled to 0-5° C. and filtered with suction. The moist crude product was elutriated in a mixture of 67.2 g of isopropanol and 100.8 g of water and washed with 200 g of water. The yield was 143.21 g (73.8%, corrected for content).


3.2. Preparation of Entacapone in the Polymorphous Form D

Instruction 1: 131.72 g of the product obtained under 3.1. were dissolved in 381.8 g of acetone and 38.2 g of water, with heating to 58° C. While still hot, this solution was added to a cold (0° C.) mixture of 1211.2 g of water, 37.5 g of acetone and 0.3 g of entacapone (polymorphous form D) in such a way that the internal temperature was maintained at 0-12° C. The suspension was then filtered with suction and the product was elutriated in 1300 g of water for 5-10 min at 0° C. After a repeat filtration, the product was washed with 130 g of water. The yield was 126.45 g (95.9%, corrected for content).


Instruction 2: 5.00 g of the product obtained under 3.1. were dissolved in 14.3 g of THF in a round-bottom flask at the boiling point. While still hot at a temperature just below the boiling point, this solution was poured into 124 g of ice-water, the flask was then rinsed with 4.0 g of THF and this solution was also added to the ice-water. The suspension was filtered at an internal temperature of 10° C. and the filter cake was washed with 15 g of ice-water and dried for 15 h at 50° C. The yield was 4.93 g (97.7%, corrected for content).


Instruction 3: 5.00 g of the product obtained under 3.1. were dissolved in 12.0 g of n-propanol at the boiling point. While still hot at a temperature just below the boiling point, this solution was poured into 40.0 g of ice-water. The suspension was filtered at an internal temperature of 23° C. and the filter cake was washed with 10 g of ice-water and dried for 15 h at 70° C. The yield was 4.64 g (93.1%, corrected for content).


EXAMPLE 4
Preparation of Entacapone in the Polymorphous Form C

5.00 g of entacapone were dissolved in 189.3 g of toluene, with heating, and added at 95° C. to 267 g of hot n-heptane, causing immediate crystallization. Half of the suspension was filtered hot at 90° C. to give 2.23 g of entacapone in the polymorphous form C. The second half of the suspension was cooled to room temperature and filtered after 14 h to give 2.57 g of entacapone, likewise in the polymorphous form C.


EXAMPLE 5
Preparation of Entacapone in the Polymorphous Form E

Instruction 1: 10.00 g of entacapone were dissolved in 28.0 g of THF, with heating, and, while still hot, added to 120 g of cold n-hexane so that the internal temperature did not exceed 10° C., causing immediate crystallization. The suspension was filtered and dried for 15 h at 50° C. to give 9.69 g of entacapone in the polymorphous form E.


Instruction 2: 10.00 g of entacapone were dissolved in 28.0 g of THF, with heating, and, while still hot, added to 120 g of cold n-pentane so that the internal temperature did not exceed 10° C., causing immediate crystallization. The suspension was filtered and dried for 15 h at 50° C. to give 9.72 g of entacapone in the polymorphous form E.


Instruction 3: 10.00 g of entacapone were dissolved in 28.0 g of THF, with heating, and, while still hot, added to 120 g of cold cyclohexane so that the internal temperature did not exceed 10° C., causing immediate crystallization. The suspension was filtered and dried for 15 h at 50° C. to give 9.56 g of entacapone in the polymorphous form E.


Instruction 4: 5.00 g of entacapone were dissolved in 41.4 g of isopropanol at the boiling point. This solution was cooled to 68° C. and poured into 126.0 g of n-hexane (internal temperature: 68° C.). The suspension was immediately filtered and the filter cake was dried for 20 h at 50° C. The yield was 4.08 g (83.2%, corrected for content).

Claims
  • 1. A crystalline form C of entacapone, characterized by the following XRD data:
  • 2. A crystalline form D of entacapone, characterized by the following XRD data:
  • 3. A crystalline form E of entacapone, characterized by the following XRD data:
  • 4. A process for the preparation of the crystalline form C of entacapone as claimed in claim 1, characterized in that entacapone is crystallized from a mixture of at least one aromatic and at least one aliphatic hydrocarbon.
  • 5. The process as claimed in claim 4, characterized in that the aromatic hydrocarbon used is toluene and the aliphatic hydrocarbon used is n-heptane.
  • 6. A process for the preparation of the crystalline form D of entacapone as claimed in claim 2, characterized in that a) entacapone is dissolved in a water-miscible solvent and this solution is added to water or a mixed aqueous system; orb) entacapone is crystallized from a non-acidic solvent or a solvent mixture with at least one non-acidic component, in the presence of a strong acid.
  • 7. The process as claimed in claim 6, variant a), characterized in that it is carried out in THF/water, acetone/water, acetone/DMSO/water or n-propanol/water.
  • 8. The process as claimed in claim 6, variant b), characterized in that it is carried out in toluene/acetonitrile or toluene/acetonitrile/acetic acid.
  • 9. The process as claimed in claim 6, variant b), or claim 8, characterized in that the acid used is hydrogen bromide.
  • 10. A process for the preparation of the crystalline form E of entacapone as claimed in claim 3, characterized in that entacapone is dissolved in a polar aprotic or alcoholic solvent and this solution is added to an aliphatic hydrocarbon immiscible with this solvent, in which entacapone is insoluble.
  • 11. The process as claimed in claim 10, characterized in that it is carried out in THF/n-hexane, THF/n-pentane, THF/cyclohexane or isopropanol/n-hexane.
  • 12. The process as claimed in claim 6, characterized in that crude entacapone is used.
  • 13. The process as claimed in claim 8, characterized in that entacapone is used in situ in the form of the product of a Knoevenagel condensation of 3,4-dihydroxy-5-nitrobenzaldehyde and 2-cyanoacetic acid diethylamide.
  • 14. The process as claimed in claim 8, characterized in that the acid used is hydrogen bromide and the process is carried out in toluene/acetonitrile/acetic acid.
  • 15. The crystalline form C, D or E of entacapone as claimed in claim 1, for use as a therapeutic active ingredient.
  • 16. A drug containing the crystalline form C, D or E of entacapone as claimed in claim 1, and a therapeutically inert excipient.
  • 17. The drug as claimed in claim 16 additionally containing levodopa and a decarboxylase inhibitor.
  • 18. The use of the crystalline form C, D or E of entacapone as claimed in claim 1, optionally in combination with levodopa and a decarboxylase inhibitor, for the treatment of Parkinson's disease or for the preparation of corresponding drugs.
  • 19. A process for the preparation of entacapone by a Knoevenagel condensation of 3,4-dihydroxy-5-nitrobenzaldehyde and N,N-diethyl-2-cyanoacetamide, characterized in that the catalyst used for this condensation is diethylamine/acetic acid.
  • 20. The process as claimed in claim 19, characterized in that the N,N-diethyl-2-cyanoacetamide used has been prepared by reacting cyanoacetic acid with diethylamine in the presence of dicyclohexylcarbodiimide.
  • 21. The process as claimed in claim 19, characterized in that the 3,4-dihydroxy-5-nitrobenzaldehyde used has been prepared by the demethylation of 5-nitrovanillin with AlCl3/pyridine in chlorobenzene.
Priority Claims (2)
Number Date Country Kind
PCT/CH03/00853 Dec 2003 CH national
940/04 Jun 2004 CH national
PCT Information
Filing Document Filing Date Country Kind 371c Date
PCT/CH04/00754 12/27/2004 WO 00 4/3/2007